Japan pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Archive — March 2025
Page 5 of 5 of this archive, newest first.
Changsha export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a MKM liraglutide lot at 96.2%, against 94.9% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The shortage years, and what they taught about interruption
The trials studied planned withdrawal. Almost nobody stops that way.
Tapering: a word borrowed from drugs with withdrawal syndromes
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
Why a dead-clean sterile filter can pass pyrogen straight through
Three compendial method families are in routine use and a fourth, based on a recombinant enzyme rather than crab lysate, is now compendial in its own right.
From the floor in Hangzhou: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
PeptideMeter result on a Hangzhou exenatide lot lands 3.5 points below the supplier’s figure
The result is unremarkable. What the report omits is not.